Biotechnology

Monday Nov 14, 2022 - 10:30 am

Odyssey Health, Inc. (ODYY) Focuses on Medical Devices Market with US Patent Application on Breath-Propelled Intranasal Delivery Device

Odyssey filed for US and global patent protection on its novel breath-propelled, intranasal brain-drug delivery device that effectively deposits concentrated drug deep into the nasal cavity for the treatment of CNS injury disease or disorderThe application follows the successful completion of the second Cohort of Odyssey’s Phase I MAD clinical trial, which saw the effective use of the device and a proven safety profile for…

Monday Nov 14, 2022 - 9:45 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Maintains Focus on Advancing Clinical Development Program for Lead Drug Candidate, Berubicin

In June 2020, CNS’ lead drug candidate, Berubicin, received Orphan Drug designation from the FDA. In June 2021, it received Fast Track designation following positive results from an extensive clinical study that saw 44% of the patients post a clinical response, with one Durable Complete ResponseWith GBM having a survival rate of only 6.8% and an average length of survival of only eight months, Berubicin…

Thursday Nov 10, 2022 - 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Maintains Strong Cash Position as It Continues Drug Development Program Pursuing Treatment for GBM

CNS Pharmaceuticals is focused on advancing its clinical development for the Berubicin drug candidate in order to bring meaningful treatment to GBM patientsGBM, which has a low survival rate, has limited treatment options when it progresses after first-line therapyThe company is looking to find a solution with Berubicin and is currently evaluating this drug candidate in a potentially pivotal global studyCNS’s ongoing R&D efforts are…

Wednesday Nov 09, 2022 - 9:45 am

Odyssey Health, Inc.’s (ODYY) PRV-002 Drug Candidate Poised to Potentially Reduce Long-Term Risks Associated with Concussion

Odyssey Health is a medical company specializing in the development of unique, life-saving medical products that provide solutions to unmet clinical needs, one of which is concussion, which currently does not have an FDA-approved drugThe company has developed the PRV-002 drug candidate, which is designed to be administered intranasally where pre-clinical results have shown to be effective in treating a concussion within 30 minutes of…

Monday Nov 07, 2022 - 10:30 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Is ‘One to Watch’

BiondVax has an exclusive worldwide license to commercialize NanoAbs for the treatment of COVID-19 The company plans to initiate a Phase 1/2a clinical trial of its inhaled COVID-19 therapeutic NanoAb in 2023 BiondVax has exclusive options for worldwide licenses for NanoAbs to treat other disorders with large, underserved needs The company has filed a Registration Statement with the SEC for an underwritten offering of shares…

Monday Nov 07, 2022 - 9:45 am

New Pharmaceutical Subsidiary Geared to Aid Odyssey Health, Inc. (ODYY) Development of Novel Solutions for Brain Related Medical Treatments

Odyssey Health Inc. is a medical product developer with a mission of filling unmet needs when it comes to acute emergencies involving patients’ central nervous systemsThe company recently announced the formation of a wholly owned subsidiary to help Odyssey develop its products as they move through the regulatory processOdyssey’s solutions include a breath-powered intranasal delivery mechanism and synthetic neurosteroids designed to provide rapid-response treatment for…

Friday Nov 04, 2022 - 9:45 am

Silo Pharma Inc. (NASDAQ: SILO) Extends Columbia University Agreement to Continue Research for Therapeutics to Treat Alzheimer’s Disease

Silo recently extended Columbia University agreement to continue research for novel therapeutics to treat Alzheimer’s disease and stress-induced anxiety disorderPreclinical studies demonstrate Silo’s jointly-developed Z-pod(TM) delivery technology holds and distributes therapeutics in a time-released manner to potentially provide targeted deliveryAdditional treatment research includes funding for the UCSF Translational Psychedelic Program to study effects of psilocybin on various inflammatory conditions Silo Pharma (NASDAQ: SILO), a developmental…

Tuesday Oct 18, 2022 - 9:45 am

Odyssey Health, Inc. (ODYY) Updates Progress of its Concussion Drug Development Program; Communicating with the FDA for permission to start phase II clinical trial of its PRV-002 Drug Candidate

Odyssey acquired IP and all rights to PRV-002, its lead drug candidate for the treatment of concussions, on March 1, 2021, and has since made notable progress in a strategic move to have the drug approved by the FDASince the acquisition, the company has completed IND enabling studies and all cohorts for Phase I SAD and MAD clinical trials for its lead drug candidateIn pre-clinical…

Monday Oct 10, 2022 - 9:00 am

Odyssey Health, Inc. (ODYY) PRV-002 Compound Takes on Heightened Significance Following Recent Concussion of Dolphins Quarterback Tua Tagovailoa, and the NFL and NFLPA’s Announcement on Changes to Concussion Protocol

The concussion controversy surrounding Tua Tagovailoa has prompted both the NFL and the NFLPA to revisit the league’s concussion protocol in a move designed to enhance player safetyIn the wake of this controversy, Odyssey is emphasizing the potential value of its PRV-002 novel compound for the treatment of concussions and the benefit of the playersAccording to a report published by Vox, there are approximately 0.41…

Thursday Oct 06, 2022 - 9:45 am

REZYFi, Inc. Addressing the Financial Needs of the ‘Largest Underbanked Industry’ in the US

REZYFi, Inc. is a real estate-oriented mortgage company servicing the needs of both traditional and non-traditional consumers and businessesThe company operates through its two subsidiaries, REZYFi Lending, which is now focused on cannabis commercial real estate lending, and ResMac, Inc., a traditional mortgage origination, correspondent, and servicing businessREZYFi seeks to provide access to financial services to the cannabis industry, which is still largely underserved because…

Thursday Oct 06, 2022 - 9:00 am

Odyssey Health, Inc. (ODYY) Completes Successful Phase I Clinical Trial Showing PRV-002 Concussion Drug Candidate was Safe and Well Tolerated

Odyssey Health is a medical company focused on unique, life-saving medical products that offer clinical advantages to unmet clinical needsWith concussion representing a high unmet need as there is currently no FDA-approved drug, Odyssey is developing a drug formulation, PRV-002, to be administered to concussed patients; the drug candidate is currently undergoing clinical evaluationIn a recent announcement, the company reported the successful completion of its…

Wednesday Oct 05, 2022 - 10:30 am

Silo Pharma Inc. (NASDAQ: SILO) Successfully Uplists, Commences Trading on the Nasdaq Market

Silo Pharma, Inc recently uplisted to the Nasdaq Capital Market, raising gross proceeds of $5 millionThe biopharmaceutical company has sought to merge traditional therapeutics and psychedelic research, entering into a series of joint ventures with leading medical universities to carry out research into the fieldMeanwhile, psychedelics are gaining increasing favour within the United States with Oregon set to begin allowing the supervised usage of psilocybin…

Tuesday Oct 04, 2022 - 9:00 am

Odyssey Health, Inc. (ODYY) Building on Safety Profile of Concussion Pharmaceutical Treatment, PRV-002, in its Phase I MAD Clinical Trial

Odyssey successfully completed the second Cohort of its Phase I MAD clinical trial, proving the safety profile of its concussion pharmaceutical treatment, PRV-002This study built on the success of Cohort I, where the drug was well tolerated and proved safe, with no severe adverse events reportedThe company’s Phase I Single Ascending Dose (“SAD”) cohorts of the clinical trial closed on July 12, 2022, proving the…

Monday Oct 03, 2022 - 10:45 am

HeartBeam Inc. (NASDAQ: BEAT) Receives US Patent for Exclusive ECG Patch Monitor Designed to Detect Heart Issues

The USPTO issued a patent for BEAT’s 12-lead electrocardiogram (“ECG”) patch monitor for detection of ACS and cardiac arrhythmiaHeartBeam has developed the only 3D-vector ECG platform for heart-attack detection anytime, anywhereBEAT’s patch technology could have a disruptive effect on the ECG patch market with its ischemia detection capability News about heart attacks and other life-threatening cardiovascular issues is alarming. Heart disease is the leading cause of…

Wednesday Sep 28, 2022 - 9:00 am

Odyssey Health, Inc.’s (ODYY) Brain-Related Drug Development Programs Taking Aim at Conditions with High Unmet Clinical Needs

Odyssey is a medical company focused on products that offer clinical advantages to unmet clinical needsIts brain-related drug development programs are currently focused on treatments for concussion and the Niemann Pick Type-C (“NPC”) disease, both of which do not currently have approved treatmentsThe company is also developing medical devices such as the intranasal drug delivery device, CardioMap, and Save-A-Life Scientists and specialists describe concussion, which…

Monday Sep 26, 2022 - 9:45 am

Odyssey Health, Inc. (ODYY) Reports Added Evidence of Proposed Concussion Therapy’s Safety at High Doses

Medical product developer Odyssey Health Inc. is dedicated to creating solutions for a variety of life-quality situations, such as early detection of heart disease, saving choking victims and treating nervous system ailmentsOdyssey Health’s primary focus has been advancing its combined device and drug solution for brain concussion injuries through the clinical test process to commercial fulfillmentThe therapeutic solution, currently known as PRV-002, is designed to…

Tuesday Sep 20, 2022 - 12:00 pm

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Clinical Trial Marks ‘Tremendous’ Milestone as First Participants Receive Initial CYB003 Dose

First dose is administered as first-ever novel psilocybin analog enters clinical developmentCybin believes CYB003 has potential to successfully address the challenges and limitations of oral psilocybinThe high level of participant interest in the study indicates a significant unmet need for alternative treatment options for major depressive disorder (“MDD”) Cybin (NEO: CYBN) (NYSE American: CYBN) has reached a milestone in its mission to create safe and effective…

Tuesday Sep 20, 2022 - 11:15 am

QSAM Biosciences Inc. (QSAM) Working to Halt, Regress Bone Tumors in Children Through Therapeutic Radiopharmaceuticals

Overall incidence of childhood cancer is on the increase, averaging 0.8% increase per year since 1975, reports leading advocacy organizationQSAM developing therapeutic radiopharmaceuticals as safer, more efficacious alternatives to address unmet medical needs, underserved patient populationsCompany creating pipeline of novel radiotherapeutics to serve multiple indications with its lead product, CycloSam With the overall incidence of childhood cancer on the rise, the work of QSAM Biosciences…

Tuesday Sep 20, 2022 - 9:00 am

HeartBeam Inc. (NASDAQ: BEAT) Is ‘One to Watch’

HeartBeam is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhereIn September 2022, the company announced it was granted a patent for its 12-lead ECG Patch Monitor, opening a pathway to ischemia and arrhythmia detection innovation in ECG Patch productsIn August 2022, the company announced it was seeking FDA approval for its HeartBeam AIMI…

Monday Sep 19, 2022 - 12:00 pm

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Participates in H.C. Wainwright 24th Annual Global Investment Conference, Presenting Key Investor Highlights on Novel Anthracycline Berubicin for GBM Treatment

Glioblastoma multiforme (“GBM”) is one of the most aggressive, deadly, and treatment-resistant forms of cancer within the brain, with an average life expectancy of 12-18 months and more than 50,000 new cases each yearThe current standard of care for GBM is ineffective for approximately 60% of patientsInitial Phase 1 trial information for Berubicin (approximately 14 years ago) resulted in one patient surviving cancer-free to present…

Thursday Sep 15, 2022 - 9:00 am

Odyssey Health, Inc.’s (ODYY) PRV-002 Drug Candidate Designed to Immediately Mitigate the Effects of Concussion on Brain Function

Odyssey Health is a medical company focused on unique, life-saving medical products that offer clinical advantages to unmet clinical needsThe company is currently developing a treatment for concussion, a condition that currently does not have an FDA-approved treatment despite having both short- and long-term consequencesThrough animal studies, Odyssey has so far evidenced that PRV-002 can easily cross the blood-brain barrier to rapidly eliminate the swelling,…

Tuesday Sep 13, 2022 - 10:30 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Takes Aim at Thus-far Incurable GBM Brain Cancer with Human Drug Trials

U.S.-based drug innovator CNS Pharmaceuticals is enrolling patients in a global clinic trial to evaluate the performance of the company’s lead drug candidate, Berubicin, in fighting glioblastomasGlioblastoma is an incurable brain cancer that is aggressive in its progression and recurrence, leaving most patients with a life expectancy of less than a year after diagnosisCNS’s efforts to fill an unmet medical need arise from promise shown…

Monday Sep 12, 2022 - 11:15 am

Odyssey Health, Inc. (ODYY) Planning Phase 2 Trials of PRV-002 for Unmet Medical Needs in Concussion Therapies

Medical costs for concussions total $20 billion in the United States, a need for which there is no FDA-approved treatmentThe CDC estimates that more than 50% of people suffering a traumatic brain injury become moderately or severely disabled and have shorter life spansOdyssey provides a portfolio of diverse technologies and related medical products to meet the unmet medical needs of concussion and TBI patients Each…

Friday Sep 09, 2022 - 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Efforts to Combat GBM Brain Cancer Proceed Amid Competitive Field

CNS Pharmaceuticals, a Texas-based cancer drug developer, is advancing testing efforts for its lead drug candidates in the fight against glioblastoma (“GBM”) and other tumorsGlioblastoma is an aggressive brain cancer that claims the lives of more than 10,000 Americans each year, with more victims worldwide, and it has no known cureCNS Pharmaceuticals’ efforts rely on establishing the safety and effectiveness of its lead candidate, BerubicinBerubicin…

Wednesday Sep 07, 2022 - 11:15 am

Odyssey Health, Inc. (ODYY) Receives Approval to Proceed with Cohort II of Its Phase I Trial’s Multiday Ascending Dosing Stage

Medical company Odyssey Health has received approval from the Safety Review Committee to start Cohort II of its Phase I trial’s Multiday Ascending Dosing (“MAD”) stageThe approval follows evidence that Odyssey’s PRV-002 concussion drug candidate was safe and well-tolerated, as seen in Cohort I of the MAD stageThe pharmacokinetic analysis also supports the hypothesis that more drug is getting to the brain itself, backing the…

Wednesday Sep 07, 2022 - 9:45 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Posts Slight Q2 2022 Performance Improvement; Maintains Priorities and Focus on Advancing its Clinical Development Program for Berubicin

CNS reported a decrease in losses from $3.8 million in Q2 2021 to $3.6 million in Q2 2022, as well as a drop in research and development expenses from $2.7 million to $2.2 million, with an increase in general and administrative expenses from $1.1 million to $1.3 millionThe company closed the quarter with $9.0 million in cash, and a working capital of approximately $10.3 million…

Wednesday Aug 31, 2022 - 11:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Pioneering Efforts as Studies, Research Show Psilocybin’s Potential in Treating AUD

A new study shows promise in treating alcohol addiction with psychedelic mushroom compound, psilocybinThese results align with efforts and expectations of Cybin, a leading ethical biopharmaceutical company championing psilocybinAfter receiving FDA approval, the company is moving forward with a first-in-human clinical trial evaluating CYB003 A new study published in JAMA Psychiatry offers hope for those struggling with alcoholism (https://ibn.fm/jV5o9), showing promise in treating alcohol addiction…

Tuesday Aug 30, 2022 - 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Looking to Fill Glioblastoma Multiforme Treatment Gap with Berubicin Drug Product

CNS Pharmaceuticals is currently undertaking a potentially pivotal global study evaluating the efficacy and safety of Berubicin compared with Lomustine administered after first-line therapy for the treatment of recurrent glioblastoma multiforme (“GBM”)GBM is an aggressive form of cancer that occurs in the brain or spinal cordIn the U.S., it affects between 12,000-15,000 new patients annually with a median survival rate of only 14.6 months from…

Friday Aug 26, 2022 - 9:45 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Leading Out in Transformation of Psychedelic Sector

Psilocybin is seeing a “research resurgence” focused on how the substance changes the brain's connectivity patternsCYBN is leading the industry in developing proprietary psychedelic-based therapeuticsThe company’s lead investigational molecule has the potential to treat major depressive disorder and alcohol use disorder The status of psilocybin is evolving as a result of mounting public acceptance and growing evidence that the substance delivers remarkable health benefits. Cybin…

Monday Aug 22, 2022 - 9:00 am

Odyssey Health, Inc. (ODYY) Continues to Report Positive Results from Ongoing Phase I Clinical Trial Evaluating Safety, Efficacy of PRV-002 Concussion Drug Candidate

Odyssey Health is a medical company focused on developing unique, life-saving medical products that offer clinical advantages for unmet clinical needsRecently, the company reported positive results from Cohort I of its Multi-Day Ascending Dosing (“MAD”) portion of its Phase I clinical trial, coming weeks after the successful completion of Phase I Single Ascending Dosing (“SAD”) clinical trialThe MAD arm thus far shows that the drug…

Wednesday Aug 17, 2022 - 9:30 am

Silo Pharma Inc. (SILO): Promising Psylocibin Study Ongoing with UCSF

Company entered scientific research agreement with UCSF in June 2021 to study psilocybin effects on various inflammatory conditions Silo Pharma (OTCQB: SILO), recently announced that the University of California San Francisco (“UCSF”) had successfully administered psilocybin to a test group of Parkinson’s disease patients as part of a scientific research agreement (“SRA”) entered with Silo in June, 2021 to “to determine the effects of psilocybin…

Thursday Aug 11, 2022 - 9:30 am

Odyssey Health, Inc. (ODYY) Redesigns Website, Corporate Presentation, to Update Information on Medical Products, Including Concussion Therapy

Odyssey Health Inc. is a medical product developer advancing treatments for conditions ranging from choking to neurodegenerative maladiesThe company’s flagship candidate is a drug-device combination for treating mild brain injuries (“MTBIs”) known as PRV-002, which is currently being used in clinical testing with human volunteersOdyssey Health recently announced a redesign of its website and an update of its corporate presentation to better communicate its efforts…

Thursday Aug 04, 2022 - 10:30 am

Odyssey Health, Inc. (ODYY) Drug Product Testing Aims to Give Military Veterans New Weapon for Fighting Brain Injury

The medical care needs of military personnel are once again in the spotlight following a political dust-up over service members’ exposure to environmental hazards at burn pitsAnother long-standing concern among service personnel is the treatment of concussive brain injuriesAlthough no FDA-approved prescription drug currently exists for treating concussions, medical product developer Odyssey Health Inc. is testing a device-drug combination designed to stop concussion injury in…

Wednesday Aug 03, 2022 - 12:00 pm

Silo Pharma Inc.’s (SILO) Ketamine Study Produces Positive Endpoint Results, Suggests Topical Formulation Reduces Neuropathic Nerve Pain

Silo recently completed ketamine study showing neuropathic nerve pain reduction when administered with patented, partnered delivery systemResults of study demonstrated Silo’s topical ketamine formulation reduced mechanical allodynia and hyperalgesia at both the pre-and post-dosing time points, mechanical hyperalgesia reduced on day seven at the pre-dose time pointKetamine typically used to induce and maintain anesthesia, drug use expanding to include depression and chronic pain treatment at…

Tuesday Aug 02, 2022 - 11:15 am

Aditxt Inc. (NASDAQ: ADTX) Seeks to Address Variability of Immune Responses

Biotech innovation company, Aditxt, Inc (“Aditxt” or the “Company”) is developing and commercializing technologies focused on monitoring and reprogramming the immune system Their ground-breaking ADi(TM) immune reprogramming platform will be initially directed towards the treatment of psoriasis, type 1 diabetes and skin allograftingThe Company has also recently begun to commercialize their AditxtScore(TM) proprietary immune mapping technology, which is designed to provide individuals with personalized reports on…

Tuesday Aug 02, 2022 - 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Expanding Scope of Potentially Pivotal Study as Part of Clinical Program to Develop GBM Treatment

CNS Pharmaceuticals is undertaking a Berubicin clinical development program targeting glioblastoma multiforme (“GBM”), the most common and devastating primary malignant brain tumorGBM has an incidence rate of 3.21 per 100,000 in the U.S. and up to 5 per 100,000 globally, with studies noting that the latter figure is risingCNS recently received approval for a protocol amendment as part of its potentially pivotal study evaluating the…

Monday Aug 01, 2022 - 11:15 am

With People in Sports and Military Service Worried About Long-Term Consequences of Traumatic Brain Injuries, Odyssey Health, Inc. (ODYY) Is Working to Offer Relief with PRV-002 Concussion Drug

Players and military service members often retire with debilitating traumatic brain injuries (“TBIs”), including concussions, that lessen the quality of life and present neurological problems as they continue to ageOdyssey has developed PRV-002, a novel compound for treating concussion, and a novel breath-propelled nasal delivery device for delivering the drug deep into the nasal cavityThe PRV-002 drug is expected to offer reprieve to people suffering…

Thursday Jul 28, 2022 - 10:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Cleared for Historic Study, Begins Enrolling Participants

Company receives FDA “may proceed” letter and investigational new drug (“IND”) application clearanceEnrollment for Phase 1/2a trial has already startedUpcoming trial is first time a psilocybin analog will be evaluated for MDD treatmentStudies show psychedelic-based treatments may have potential to revolutionize mental healthcare, but few companies have assessed limitations of oral psilocybin In a first-ever milestone, Cybin (NEO: CYBN) (NYSE American: CYBN) received approval from the…

Thursday Jul 28, 2022 - 9:00 am

Pro Athletes Provide Specialized Advocacy for Odyssey Health, Inc.’s (ODYY) Solution for Concussion-related Brain Injuries

CDC estimates put the incidence of athlete concussion incidents at 5 to 10 percent of playersCurrently, there is no FDA-approved medicinal treatment for helping people with concussion injuriesOdyssey Health Inc. is a company developing a drug-device combination to treat concussion patients in the first minutes after injuryRetired pro soccer and football athletes Abby Wambach, Kurt Warner, and Brett Favre, have formed a Sports Advisory Board…

Tuesday Jul 26, 2022 - 9:00 am

Odyssey Health, Inc. (ODYY), Determined to Introduce the Market’s First FDA Approved Concussion Treatment Drug

PBS News Hour estimates that, for college students, concussions cost between $446 million and $1.5 billion annually, while for high school students the cost ranges from $5.4 billion to $19.2 billionOdyssey, through its flagship product, PRV-002, hopes to offer the first FDA-approved drug treatment for concussionsOnce approved, Odyssey is confident that PRV-002 will bring relief to thousands of victims, reduce the cost of concussion treatment…

Articles

Articles Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions